Modalis Therapeutics Corporation (TOKYO: 4883) today announced that its research article titled “Efficient LAMA1 gene activation by epigenome editing as a therapeutic approach for LAMA2-CMD” has been ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Add Yahoo as a preferred source to see more of our stories on Google. A sign marks the Novartis Institutes for BioMedical Research facility in Cambridge, Massachusetts, U.S., June 16, 2021.

Nov 24 (Reuters) - (This Nov 24 story has been corrected to fix the pricing for Zolgensma to $2.5 million from $2.1 million in paragraph 4) The U.S. Food and Drug Administration has approved Novartis' ...

Immunotherapy has revolutionized the way physicians treat patients. Previously, chemotherapy was the standard-of-care with the goal to eliminate tumor cells by dysregulating their ability to ...

TUCSON, Ariz. (KVOA) - Carondelet St. Mary’s Hospital has achieved a milestone by completing its first procedure to implant the Barostim™ Baroreflex Activation Therapy device. This innovative heart ...

TUCSON, Ariz. (KVOA) - Carondelet St. Mary's Hospital has successfully completed its first implantation of the Barostim™ Baroreflex Activation Therapy device, marking a significant advancement in the ...

GLP-1 receptor agonists (GLP-1RAs) are used in the management of obesity and type 2 diabetes. Originally developed as glucose-lowering medications, these agents have also been shown to result in ...

Texas Muscle Activation opened a second location in the Dallas-Fort Worth area in Southlake, providing pain relief options. The original location is in Frisco. (Courtesy Texas Muscle Activation) A ...

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today ...

Duchenne therapy may be evolving from slowing disease to reversing it—with RNA approaches offering the prospect of restoring function. Ongoing research will determine if these advances can deliver ...